Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. Viking expects to report data from the study in the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal
- Viking manufacturing agreement removes key overhang, says Morgan Stanley
- Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects